Literature DB >> 31355241

A case of chemorefractory metastatic type AB thymoma sensitive to helical tomotherapy.

Zelai He1,2, Huijun Zhang3, Zhen Cui1,2, Qijun Jing1,2, Zhe Zhang1,2, Yong Shen4, Jingjing Liu1,2, Jingwen Huang2,4.   

Abstract

Type AB thymoma associated with multiple metastases is rarely encountered. This paper describes the therapeutic effect of new radiotherapy, helical tomotherapy (TOMO), in a thymoma patient with multiple metastases. A male patient aged 52 was diagnosed as type AB thymoma with multiple metastases. Two-cycle chemotherapy was administered as the primary therapy. The efficacy evaluation indicated progressive disease (PD), so radiotherapy was added to the initial treatment. The re-evaluation of efficacy indicated PD under chemotherapy and partial response (PR) in the radiotherapy area, so the latter treatment was changed to TOMO. The TOMO treatment was effective. However, due to the severe bone marrow suppression, the radiotherapy was stopped, and the patient was discharged. We concluded that the development of type AB thymoma associated with multiple metastases was fast, and the patient was sensitive to radiotherapy but not chemotherapy. Thus, TOMO can be selected as the primary palliative therapeutic regimen for chemotherapy-resistant thymoma patients, but the patient tolerance of TOMO requires careful evaluation and further clinical study.

Entities:  

Keywords:  Thymoma; chemotherapy; metastasis; radiotherapy; tomotherapy (TOMO)

Year:  2019        PMID: 31355241      PMCID: PMC6614316          DOI: 10.21037/atm.2019.05.34

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  1 in total

1.  Anlotinib Combined with Cranial Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Retrospectively, Control Study.

Authors:  Zelai He; Jia Liu; Yuwei Ma; Hao Jiang; Zhen Cui; Guowen Wang; Yufeng Wu; Jiuzhou Liu; Xixi Cai; Jing Qian; Jingwen Huang; Huijun Zhang; Hongwei Li
Journal:  Cancer Manag Res       Date:  2021-08-04       Impact factor: 3.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.